Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02119663 · ClinicalTrials.gov registry record · Phase 3
A Study of Ruxolitinib in Pancreatic Cancer Patients
A Phase 3 study, sponsored by Incyte Corporation.
- Terminated
- Registry status
- Phase 3
- Development phase
- 86
- Enrollment target
NCT02119663: Clinical Trial Phase 3 study, sponsored by Incyte Corporation.
NCT02119663 is a Phase 3 study that was terminated before completion, run by Incyte Corporation. The registered enrollment target is 86 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (89% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02119663, a Phase 3 study, was terminated before completion, sponsored by Incyte Corporation.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 86 participants
- Enrollment target
Study Summary
This was to determine the efficacy, based upon overall survival, of ruxolitinib added to capecitabine for the treatment of metastatic pancreatic cancer.
Primary Outcome
Overall survival is reported here based on the number of deaths from randomization until the data cut-off.
Interventions
- DRUG Placebo
- DRUG Capecitabine
- DRUG Ruxolitinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 86 participants |
| Start Date | 2014-06 |
| Est. Completion | 2016-10 |
| Phase | Phase 3 |
Why NCT02119663 stopped before completion
NCT02119663 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 86 participants, a relatively small participant target, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (89% lower).
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT02119663 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02119663 about?
NCT02119663 is a clinical study titled "A Study of Ruxolitinib in Pancreatic Cancer Patients". This was to determine the efficacy, based upon overall survival, of ruxolitinib added to capecitabine for the treatment of metastatic pancreatic cancer.
What is the current status of trial NCT02119663?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 86 participants. The study started on 2014-06. Estimated completion is 2016-10.
What interventions are being tested in trial NCT02119663?
The interventions under investigation include: Placebo (DRUG), Capecitabine (DRUG), Ruxolitinib (DRUG).
Who is sponsoring clinical trial NCT02119663?
This trial is sponsored by Incyte Corporation, which has 239 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02119663's enrollment target sits among peer trials
86 1745th of 2000 higher than 254 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01639508 · 86 participants · Phase 2
Cabozantinib in Patients With RET Fusion-Positive Advanced Non-Small Cell Lung Cancer and Those With Other Genotypes: ROS1 or NTRK Fusions or Increased MET or AXL Activity
- NCT03519269 · 86 participants · NA
Navio Robotic Versus Conventional Total Knee Arthroplasty
- NCT04132999 · 86 participants · NA
PAP for Children With DS and OSAS
- NCT04545957 · 86 participants · NA
Jump: MR Simulation For Radiation Therapy Master Protocol
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia